Roche Prepares Faricimab For Filing After Phase III AMD Data
Non-Inferior To Eylea With Longer Dosing Intervals
Top-line Phase III data for faricimab in age-related macular degeneration leave Roche poised to file the bi-specific antibody for retinal diseases, but again there is no advantage with the novel dual-acting product over Eylea.
You may also be interested in...
While its NDA languishes at the US Food and Drug Administration, the EMA’s CHMP has said yes to dostarlimab’s marketing in the EU for endometrial cancer.
After a baptism of fire during the coronavirus pandemic, mRNA vaccine technology has earned its stripes. In less than a year, mRNA vaccines have been catapulted from interesting pipeline prospects to game-changers in the fight against COVID-19. But what does this success mean for the future of the technology?
The Phase III KESTREL study evaluating Imfinzi missed its primary overall survival benefit and a key secondary outcome in first-line recurrent or metastatic head and neck squamous cell carcinoma.